Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta™) in patients with schizophrenia

International Journal of Neuropsychopharmacology

Volumn 8, Issue 1, 2005, Pages 27-36

  Gefvert, Ola ^a   Eriksson, Bo ^b   Persson, Per ^c   Helldin, Lars ^c   Björner, Annika ^d   Mannaert, Erik ^e   Remmerie, Bart ^e   Eerdekens, Mariëlle ^e   Nyberg, Svante ^f  

^a UPPSALA UNIVERSITY   (Sweden)

^b Janssen Cilag   (Sweden)

^c Norra Alvsborgs Lans Landsting ^*  (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Dopamine d2; Long acting risperidone; Pharmacokinetics; Receptors

Indexed keywords

ANTIPARKINSON AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CIMETIDINE; DOPAMINE 2 RECEPTOR; FLUOXETINE; KETOCONAZOLE; LONG ACTING DRUG; MICONAZOLE; OMEPRAZOLE; PALIPERIDONE; PHENYTOIN; RACLOPRIDE C 11; RADIOLIGAND; RIFAMPICIN; RISPERIDONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RECEPTOR BINDING; FEMALE; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; STEADY STATE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; BRAIN; DELAYED-ACTION PREPARATIONS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INJECTIONS, INTRAMUSCULAR; ISOXAZOLES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINES; RADIOIMMUNOASSAY; RECEPTORS, DOPAMINE D2; RISPERIDONE; SCHIZOPHRENIA; SCINTILLATION COUNTING;

EID: 15244341031     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145704004924     Document Type: Article

References (25)

1. Beasley Jr. CM, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, Blin O, Beuzen J-N (1997). Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology 7, 125-137.
2. Carpenter Jr. WT, Buchanan RW, Kirkpatrick B, Lann HD, Breier AF, Summerfelt AT (1999). Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. American Journal of Psychiatry 156, 412-418.
3. Davis J (1975). Overview: maintenance therapy in psychiatry. American Journal of Psychiatry 132, 1237-1245.
4. Davis JM, Metalon L, Watanabe MD, Blake L (1994). Depot antipsychotic drugs: place in therapy. Drugs 47, 741-773.
5. Dencker SJ, Gios I, Martensson E, Norden T, Nyberg G, Persson R, Roman G, Stockman O, Svard KO (1994). A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients. Psychopharmacology (Berlin) 114, 24-30.
6. Farde L, Eerdekens M, Eriksson B, Mannaert E, Wetterberg L (2002). Relationships between plasma concentrations, D2-receptor occupancy, and efficacy of Risperdal Consta™. American College of Neuropsychopharmacology 41st Annual Meeting, 8-12 December, 2002, San Juan, Puerto Rico. Scientific Abstract, p. 180.
7. 11C]raclopride binding to D2-dopamine receptors studied by PET - a comparison to the equilibrium analysis. Journal of Cerebral Blood Flow and Metabolism 9, 696-708.
8. Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedall G (1992). Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine - relation to extrapyramidal side effects. Archives of General Psychiatry 49, 538-544.
9. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca P-M, Chrzanowski W, Martin S, Gefvert O (2003). Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. Journal of Clinical Psychiatry 64, 1250-1257.
10. Gerlach J (1994). Oral versus depot administration of neuroleptics in relapse prevention. Acta Psychiatrica Scandinavica 382, (Suppl.), 28-32.
11. Gilbert PL, Harris MJ, McAdams LA, Jeste DV (1995). Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Archives of General Psychiatry 52, 73-88.
12. Halldin C, Farde L, Hogberg T, Hall H, Strom P, Ohlberger A, Solin O (1991). A comparative study of five carbon-11 or fluorine-18 labeled salicylamides. Preparation and in vitro dopamine D-2 receptor binding. International Journal of Radiation Applications and Instrumentation B 18, 871-881.
13. Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment-resistant schizophrenic : a double-blind comparison with chlorpromazine. Archives of General Psychiatry 45, 789-796.
14. Kane JM (1995). Dosing issues and depot medication in the maintenance treatment of schizophrenia. International Clinical Psychopharmacology 10 (Suppl. 3), 65-71.
15. Kane JM, Eerdekens M, Lindenmayer J-P, Keith SJ, Lesem M, Karcher K (2003). Long-acting risperidone: efficacy and safety of the first long-acting atypical antipsychotic. American Journal of Psychiatry 160, 1125-1132.
16. Kapur S, Zipursky RB, Remington G (1999). Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. American Journal of Psychiatry 156, 286-293.
17. Marder SR, Meibach RC (1994). Risperidone in the treatment of schizophrenia. American Journal of Psychiatry 141, 825-835.
18. Nordström AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G (1993). Central D2-dopamine receptor occupancy in relation to antipsychotic drug effect: a double-blind PET study of schizophrenic patients. Biological Psychiatry 33, 227-235.
19. Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L (1999). Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. American Journal of Psychiatry 156, 869-875.
20. Ramstack M, Grandolfi GP, Mannaert E, D'Hoore P, Lasser RA (2003). Long-acting risperidone: prolonged-release injectable delivery of risperidone using Medisorb microsphere technology. Abstracts of the IXth International Congress on Schizophrenia Research. Colorado Springs, 29 March-2 April 2003. Schizophrenia Research 60 (Suppl.), 314.
21. Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, Hargreaves WA, Kane JM, Ninan PT, Frances A, Jacobs M, Lieberman JA, Mance R, Simpson GM, Woerner MG (1997). Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Archives of General Psychiatry 54, 453-463.
22. Tuninger E, Levander S (1996). Large variations of plasma levels during maintenance treatment with depot neuroleptics. British Journal of Psychiatry 169, 618-621.
23. Wienhart K, Dahlbom M, Eriksson L, Michel C, Bruckbauer T, Pietrzyk U (1994). The ECAT EXACT HR: performance of a new high resolution positron scanner. Journal of Computer Assisted Tomography 18, 110-118.
24. Wistedt B (1981). A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiatrica Scandinavica 64, 65-84.
25. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue CY, Cooper TB, Brodie JD (1989). Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. American Journal of Psychiatry 146, 905-908.